Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Risk of Anal Cancer Following Benign Anal Disease and Anal Cancer Precursor Lesions: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A Cohort Study of Breast Cancer Risk after 20 Years of Follow-Up of Women Treated with Fertility Drugs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genetic variation at PPP1R3B increases hepatic CT attenuation and interacts with prandial status on plasma glucose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of Glucose Level on Micro- and Macrovascular Disease in the General Population: A Mendelian Randomization Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
  • The PRACTICAL Consortium(Peter Iversen, Martin Andreas Røder, members)
Vis graf over relationer

BACKGROUND: Genome-wide association studies have identified multiple genetic variants associated with prostate cancer risk which explain a substantial proportion of familial relative risk. These variants can be used to stratify individuals by their risk of prostate cancer.

METHODS: We genotyped 25 prostate cancer susceptibility loci in 40,414 individuals and derived a polygenic risk score (PRS). We estimated empirical odds ratios (OR) for prostate cancer associated with different risk strata defined by PRS and derived age-specific absolute risks of developing prostate cancer by PRS stratum and family history.

RESULTS: The prostate cancer risk for men in the top 1% of the PRS distribution was 30.6 (95% CI, 16.4-57.3) fold compared with men in the bottom 1%, and 4.2 (95% CI, 3.2-5.5) fold compared with the median risk. The absolute risk of prostate cancer by age of 85 years was 65.8% for a man with family history in the top 1% of the PRS distribution, compared with 3.7% for a man in the bottom 1%. The PRS was only weakly correlated with serum PSA level (correlation = 0.09).

CONCLUSIONS: Risk profiling can identify men at substantially increased or reduced risk of prostate cancer. The effect size, measured by OR per unit PRS, was higher in men at younger ages and in men with family history of prostate cancer. Incorporating additional newly identified loci into a PRS should improve the predictive value of risk profiles.

IMPACT: We demonstrate that the risk profiling based on SNPs can identify men at substantially increased or reduced risk that could have useful implications for targeted prevention and screening programs.

OriginalsprogEngelsk
TidsskriftCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Vol/bind24
Udgave nummer7
Sider (fra-til)1121-9
Antal sider9
ISSN1055-9965
DOI
StatusUdgivet - jul. 2015

ID: 45701108